Surgery-Free Rectal Cancer Treatment Edges Closer as Dostarlimab Clears Registrational Trial
GSK announced Sunday that dostarlimab (Jemperli), its PD-1–blocking immunotherapy, met the primary endpoint of the AZUR-1 registrational Phase…
GSK reports Jemperli rectal cancer trial results
GSK reported positive interim results from the AZUR-1 Phase II trial of Jemperli in dMMR/MSI-H locally advanced rectal…
GSK’s Jemperli meets main goal in mid-stage rectal cancer trial
GSK said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a…
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio Proactive uses images sourced from Shutterstock GSK…